TrialCardiovascular diabetology2020

Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study).

Manjunath Krishnappa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.